Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' reply.

Genovese, Mark C; Buckley, Christopher D; Saurigny, Didier; Schett, Georg; Davy, Katherine; Gupta, Anubha; Smith, Julia E; Patel, Jatin; Tak, Paul P

Genovese, Mark C; Buckley, Christopher D; Saurigny, Didier; Schett, Georg; Davy, Katherine; Gupta, Anubha; Smith, Julia E; Patel, Jatin; Tak, Paul P.

Afiliação

Genovese MC; Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA.
Buckley CD; Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Saurigny D; ImmunoInflammation, GlaxoSmithKline, Stevenage SG1 2NY, UK.
Schett G; Department of Internal Medicine 3, University of Erlangen-Nurnberg and Universitatsklinikum Erlangen, Erlangen, Germany.
Davy K; Statistics, GlaxoSmithKline, Stevenage SG1 2NY, UK.
Gupta A; Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Stevenage SG1 2NY, UK.
Smith JE; ImmunoInflammation, GlaxoSmithKline, Stevenage SG1 2NY, UK.
Patel J; ImmunoInflammation, GlaxoSmithKline, Middlesex, UK.
Tak PP; Research and Development, GlaxoSmithKline, Stevenage SG1 2NY, UK. Electronic address: tak.paulpeter@gmail.com.

Lancet Rheumatol ; 3(7): e473-e474, 2021 Jul.

Article em En | MEDLINE | ID: mdl-38279397

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Lancet Rheumatol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google